Connected inhalers raise adherence. Better asthma control is the harder claim

Connected inhalers — the ones with a Bluetooth sensor clipped on, or a dose counter and reminder built in — do the first thing they promise: they measurably increase how reliably people take their controller medication. What is harder to show is the thing that actually matters, that better adherence delivers better disease control. The evidence for the adherence gain is strong; the evidence that it lowers attacks and symptoms is real but consistently smaller [s1][s2].

The adherence signal is solid

A 2023 systematic review and meta-analysis in Pharmaceuticals pooled 18 studies — eight observational and ten clinical trials — of electronic monitoring devices for inhalers in adults with asthma or COPD [s1]. For adherence measured over periods longer than three months, the devices came out clearly ahead: a standardised mean difference of 0.36 (95% CI, 0.25 to 0.48) under a fixed-effects model, and 0.41 (0.22 to 0.60) under a random-effects model [s1]. Both intervals sit well above zero, which is why the adherence claim is the one part of this field that is not in dispute.

The most-cited single trial makes the size of the effect concrete. In a randomised controlled trial of school-aged children in Auckland who had come to the emergency department with an asthma attack, an inhaler with the audiovisual reminder function switched on produced median adherence of 84%, against 30% in children whose device recorded doses but kept the reminder switched off [s2]. That is a large gap, and it isolates the mechanism: the recording alone did little; the nudge did the work.

The control signal is weaker

Here the picture gets more honest. The same meta-analysis found that when it looked at asthma control, the improvement was modest and fragile: an exploratory analysis of Asthma Control Test scores gave a standardised mean difference of 0.25 (95% CI, 0.11 to 0.39) under a fixed-effects model, but 0.47 with a wide interval of −0.14 to 1.08 under a random-effects model — an interval that crosses zero [s1]. In plainer terms, the control benefit is there in some analyses and vanishes in others, and other clinical outcomes across the review "showed mixed results" [s1].

The Auckland trial illustrates the same divergence. Despite tripling adherence, it found essentially no difference in the pragmatic outcome it had co-designated as primary — the proportion of school days missed was 1.9% in the reminder group and 1.7% in the control group [s2]. Asthma morbidity did improve more in the reminder group, falling by 2.0 points versus 1.2 points on a symptom score (p=0.008) — a genuine but small edge [s2]. The lesson is that adherence is a means, not an end: pushing doses up helps most in the subset of patients whose poor control is actually caused by missed doses, and less in everyone else.

The breadth of the evidence base is worth being honest about, too. The meta-analysis rested on 18 studies, only 10 of them clinical trials, and it described its own asthma-control finding as "exploratory" — language that signals the analysis was hypothesis-generating rather than definitive [s1]. Most of these studies also ran for months, not years, so they speak to whether a reminder lifts adherence over a season, not to whether people keep using the device once the novelty fades — a well-documented failure mode for consumer health hardware. COPD, where much of the commercial interest sits, is represented more thinly still. The adherence effect is real; the claim that connected inhalers change the long-run course of these diseases is not yet something the trials can support [s1].

Why the gap exists

Two things blunt the translation from adherence to outcomes. First, many people with uncontrolled asthma or COPD are uncontrolled for reasons a reminder cannot fix — wrong inhaler technique, the wrong drug, smoking, allergen exposure, or disease that is simply severe. Second, the meta-analysis noted that the added value often came not from the gadget alone but from a clinician acting on the data it produced [s1]. A sensor that logs adherence to a dashboard nobody reviews is a data-collection device, not a treatment. This is the same limit that constrains algorithms built to predict which patients will stop taking their medicines: prediction and measurement are upstream of the human follow-up that changes anything.

What this means for a reader

For someone whose asthma flares because they forget their preventer, a reminder-enabled or connected inhaler is one of the better-supported consumer health technologies going — the adherence effect is large and replicated [s1][s2]. But the device is a prompt, not a controller-medication upgrade, and it works best inside a care relationship where the adherence data is reviewed and acted on. It does not substitute for getting the reliever-and-preventer strategy itself right, which is where the largest gains in control still come from. Buying the connected inhaler is the easy part; the benefit shows up only when the extra doses were the missing ingredient.

Sources

• [s1] Pharmaceuticals — Clinical Impact of Electronic Monitoring Devices of Inhalers in Adults with Asthma or COPD: A Systematic Review and Meta-Analysis (2023-03-08)
• [s2] The Lancet Respiratory Medicine — The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial (2015-01-21)